###begin article-title 0
TAF6delta Controls Apoptosis and Gene Expression in the Absence of p53
###end article-title 0
###begin p 1
Conceived and designed the experiments: AB BB. Performed the experiments: EW. Analyzed the data: FP AB BB. Wrote the paper: EW AB BB.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 348 356 348 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
Life and death decisions of metazoan cells hinge on the balance between the expression of pro- versus anti-apoptotic gene products. The general RNA polymerase II transcription factor, TFIID, plays a central role in the regulation of gene expression through its core promoter recognition and co-activator functions. The core TFIID subunit TAF6 acts in vitro as an essential co-activator of transcription for the p53 tumor suppressor protein. We previously identified a splice variant of TAF6, termed TAF6delta that can be induced during apoptosis.
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
To elucidate the impact of TAF6delta on cell death and gene expression, we have employed modified antisense oligonucleotides to enforce expression of endogenous TAF6delta. The induction of endogenous TAF6delta triggered apoptosis in tumor cell lines, including cells devoid of p53. Microarray experiments revealed that TAF6delta activates gene expression independently of cellular p53 status.
###end p 5
###begin title 6
Conclusions
###end title 6
###begin p 7
Our data define TAF6delta as a pivotal node in a signaling pathway that controls gene expression programs and apoptosis in the absence of p53.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 342 345 342 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Hengartner1">[1]</xref>
###xml 458 461 458 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Thompson1">[2]</xref>
###xml 388 393 <span type="species:ncbi:9606">human</span>
###xml 651 656 <span type="species:ncbi:9606">human</span>
Tightly controlled programmed cell death is essential for the development and tissue homeostasis of all animals. Metazoan cells possess an evolutionary conserved network of proteins (e.g. caspases, Bcl-2 family members and death receptors) that execute appropriate life or death decisions in response to extrinsic and intrinsic cellular cues [1]. Deregulated apoptosis underlies numerous human disease states including neurodegenerative disorders and cancer [2]. The identification and molecular characterization of the critical control points in apoptotic pathways is therefore essential to reveal novel therapeutic avenues to treat a broad array of human pathologies.
###end p 9
###begin p 10
###xml 202 205 202 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Fesus1">[3]</xref>
###xml 457 460 457 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Kumar1">[4]</xref>
###xml 493 496 493 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Schwerk1">[5]</xref>
###xml 793 796 793 796 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Vousden1">[6]</xref>
###xml 965 969 965 969 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FDXR</italic>
###xml 969 972 969 972 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Liu1">[7]</xref>
###xml 974 977 974 977 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Hwang1">[8]</xref>
###xml 979 983 979 983 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PUMA</italic>
###xml 983 986 983 986 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Yu1">[9]</xref>
###xml 988 992 988 992 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Noxa</italic>
###xml 992 996 992 996 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Oda1">[10]</xref>
###xml 1002 1006 1002 1006 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Miyashita1">[11]</xref>
###xml 1011 1018 1011 1018 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53AIP1</italic>
###xml 1018 1022 1018 1022 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Oda2">[12]</xref>
Gene expression plays a key role in the response of cells to death-inducing stimuli. A growing body of evidence indicates that the levels of numerous death-related genes can be induced during apoptosis [3]. The integration of cellular signals from diverse apoptotic pathways requires the finely balanced expression of pro- versus anti-apoptotic proteins. Gene expression patterns of pro- and anti-apoptotic genes, established by the levels of transcription [4] as well as alternative splicing [5], can dictate the life-or-death decisions of cells. The most intensely studied protein known to control apoptosis by altering gene expression is the p53 tumor suppressor. Current paradigms link the p53 tumor suppression function to its capacity to induce apoptosis in response to genotoxic stress [6]. The pro-apoptotic activity of p53 depends largely on its function as a transcriptional activator that binds directly to the promoters of pro-apoptotic genes including FDXR[7], [8], PUMA[9], Noxa[10], Bax [11] and p53AIP1[12].
###end p 10
###begin p 11
###xml 239 243 239 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Bell1">[13]</xref>
###xml 245 249 245 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Green1">[14]</xref>
###xml 451 455 451 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Muller1">[15]</xref>
###xml 579 583 579 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Albright1">[16]</xref>
###xml 779 783 779 783 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Gangloff1">[17]</xref>
###xml 835 839 835 839 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Xie1">[18]</xref>
###xml 852 856 852 856 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Werten1">[19]</xref>
###xml 867 871 867 871 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Birck1">[20]</xref>
###xml 884 888 884 888 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Gangloff2">[21]</xref>
###xml 904 908 904 908 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Gangloff3">[22]</xref>
###xml 1040 1050 1040 1050 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
###xml 1111 1115 1111 1115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Wright1">[23]</xref>
###xml 1040 1050 <span type="species:ncbi:7227">Drosophila</span>
TFIID is a multi-protein complex that plays a pivotal role in the transcription of protein-coding genes in eukaryotes. TFIID is composed of the TATA-binding protein (TBP) and up to 14 evolutionarily conserved TBP-associated factors (TAFs) [13], [14]. TFIID can play a rate-limiting role in the regulation of transcription through the recognition of the core promoter elements such as the TATA-box, the initiator, and downstream promoter element (DPE) [15]. The TFIID complex also engages in direct contacts with DNA-binding transcriptional factors to co-activate gene expression [16]. The architecture and integrity of TFIID complexes depends on a network of TAF-TAF interactions that are predominantly mediated by dimerization of TAFs via their interlocking histone fold motifs [17]. Histone-fold pairs within TFIID include TAF6-TAF9 [18], TAF4-TAF12 [19], TAF11-13 [20], TAF8-TAF10 [21] and TAF3-TAF10 [22]. TAF4 and TAF5 together with the histone fold containing TAF12, TAF9 and TAF6 are defined as core TAFs, since their depletion from Drosophila cells results in overall destabilization of TFIID complexes [23].
###end p 11
###begin p 12
###xml 33 35 33 35 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">II</sub>
###xml 152 153 152 153 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 181 185 181 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Michel1">[24]</xref>
###xml 304 308 304 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Shen1">[25]</xref>
###xml 369 373 369 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Michel1">[24]</xref>
###xml 375 379 375 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Poon1">[26]</xref>
###xml 388 392 388 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Lago1">[27]</xref>
###xml 402 406 402 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Aoyagi1">[28]</xref>
###xml 416 420 416 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Amsterdam1">[29]</xref>
###xml 533 537 533 537 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TAF6</italic>
###xml 543 547 543 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Purrello1">[30]</xref>
###xml 549 553 549 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Weinzierl1">[31]</xref>
###xml 128 133 <span type="species:ncbi:4932">yeast</span>
###xml 261 266 <span type="species:ncbi:4932">yeast</span>
###xml 363 368 <span type="species:ncbi:4932">yeast</span>
###xml 507 512 <span type="species:ncbi:9606">human</span>
###xml 599 604 <span type="species:ncbi:9606">human</span>
The core TFIID subunit TAF6 (hTAFII70/80) has been shown to be broadly required for RNA polymerase II (Pol II) transcription in yeast when total poly(A)+ mRNA levels were monitored [24]. A more recent microarray analysis estimated that approximately 18% of the yeast Pol II transcriptome depends on TAF6 [25]. TAF6 has been shown to be essential for viability in yeast [24], [26], plants [27], insects [28] and fish [29]. The requirement for TAF6 in all model organisms studied, together with the fact that human cells have a single TAF6 gene [30], [31], strongly implies that TAF6 is essential for human cell viability.
###end p 12
###begin p 13
###xml 76 80 76 80 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Burke1">[32]</xref>
###xml 82 86 82 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Shao1">[33]</xref>
###xml 212 220 212 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 259 263 259 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Thut1">[34]</xref>
###xml 299 303 299 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Lu1">[35]</xref>
###xml 541 548 541 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 548 552 548 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Farmer1">[36]</xref>
###xml 554 558 554 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Jimenez1">[37]</xref>
###xml 560 564 560 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Johnson1">[38]</xref>
TAF6 and TAF6-TAF9 dimers can bind to the downstream promoter element (DPE) [32], [33]. In addition to its core promoter recognition function, TAF6 can also interact with transcriptional activators. For example, in vitro experiments have shown that both TAF6 [34], and its dimerization partner TAF9 [35], interact directly with p53 and are required for the activation of transcription by p53. The available evidence implies that the TAF6-p53 interaction is required for the activation of at least some, and potentially all, p53 target genes in vivo[36], [37], [38].
###end p 13
###begin p 14
###xml 138 142 134 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Bell2">[39]</xref>
###xml 755 759 731 735 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Thut1">[34]</xref>
We have identified and characterized a splice variant termed TAF6delta that lacks 10 amino acids in the centre of its histone fold domain [39]. TAF6delta is unable to interact with TAF9, but retains interactions with other TFIID subunits. TAF6delta expression is induced in promyelocytic HL-60 cells undergoing retinoic-acid dependent apoptosis. TAF6delta overexpression induces apoptosis in HeLa cells, evoking the possibility that TFIID function could be coupled to certain apoptotic pathways via TAF6delta. Importantly, however, it is not currently known if changes in the expression of endogenous TAF6delta can influence tumor cell death. Furthermore, despite the physical and functional interactions between the pivotal tumor suppressor p53 and TAF6 [34], nothing is currently known about whether p53 is required for TAF6delta-mediated apoptosis. Here, we have used splice-site switching modified antisense RNA technology to demonstrate that endogenous TAF6delta controls apoptosis and that p53 is not required for TAF6delta-dependent apoptosis or TAF6delta-dependent gene expression.
###end p 14
###begin title 15
Materials and Methods
###end title 15
###begin title 16
Cell culture
###end title 16
###begin p 17
HeLa cells were grown in DMEM containing 2.5% CS and 2.5% FCS. Saos-2 and H1299 cell lines were cultured in DMEM with 10% FCS. A549 cells were grown in Ham's F12 medium with 10% FCS. HCT-116 cells were grown in McCoy's media supplemented with 10% FCS. When indicated, cells were treated with the proteasome inhibitor MG-132 (Calbiochem) at 0.5 microM and/or pan-caspase inhibitor Z-VAD-FMK (Biomol) at 100 microM.
###end p 17
###begin title 18
Transfections
###end title 18
###begin p 19
###xml 259 285 255 281 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CGAUCUCUUUGAUGCGGUAG-3&#8242;</named-content>
###xml 367 393 363 389 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GCCGGGUCACCUGUGCGAUC-3&#8242;</named-content>
###xml 446 472 442 468 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-AUGGCCUCGACGUGCGCGCU-3&#8242;</named-content>
###xml 533 557 529 553 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-ACCCAGCCGCCGUUCUCC-3&#8242;</named-content>
###xml 593 594 589 590 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</sub>
###xml 594 598 590 594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Mercatante1">[40]</xref>
Oligonucleotides were transfected with lipofectamine 2000 (Invitrogen) as a delivery agent (1.6 microl/ml) according to the manufacturer's recommendations. 2'-O-methyl-oligoribonucleoside phosphorothioate antisense 20-mers were from Sigma-Proligo. "TAF6 AS1" 5'-CGAUCUCUUUGAUGCGGUAG-3' targets the central 20 nucleotides of the alternative exon 2 of TAF6, "TAF6 AS2" 5'-GCCGGGUCACCUGUGCGAUC-3' the constitutive alpha 5' splice site. "Control AS" 5'-AUGGCCUCGACGUGCGCGCU-3' is a scrambled oligo used as a negative control. "Bcl-x AS" 5'-ACCCAGCCGCCGUUCUCC-3' targets the 5'-splice site of Bcl-xL[40]. Plasmids were transfected using 1 microl DMRIE-C (Invitrogen) as a delivery agent in a 24 well plate according to the manufacturer's recommendations. All transfections were performed in OptiMEM medium (Invitrogen).
###end p 19
###begin title 20
RT-PCR
###end title 20
###begin p 21
###xml 428 456 394 422 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-ATGGGCATCGCCCAGATTCAGG-3&#8242;</named-content>
###xml 469 497 435 463 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-AAGGCGTAGTCAATGTCACTGG-3&#8242;</named-content>
###xml 518 545 484 511 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-TCATTTCCGACTGAAGAGTGA-3&#8242;</named-content>
###xml 558 585 524 551 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-ATGGCAGCAGTAAAGCAAGCG-3&#8242;</named-content>
###xml 161 164 <span type="species:ncbi:11866?0.5863095238095238|species:ncbi:12321?0.21726190476190477">AMV</span>
Total RNA was isolated from cells using Trizol (Invitrogen) according to the manufacturer's recommendations. 1 microg of total RNA was reverse transcribed using AMV-RT (Roche). 1/10 of the total cDNA was used per PCR reaction : 95degreesC, 3 min; 25 cycles of 94degreesC for 1 min, 58degreesC for 45 sec, 68degreesC for 50 sec; final extension at 68degreesC for 5 min with the following oligonucleotide pairs. For Taf6; forward 5'-ATGGGCATCGCCCAGATTCAGG-3' and reverse 5'-AAGGCGTAGTCAATGTCACTGG-3'. For Bcl-x; forward 5'-TCATTTCCGACTGAAGAGTGA-3' and reverse 5'-ATGGCAGCAGTAAAGCAAGCG-3'
###end p 21
###begin title 22
Apoptosis assays
###end title 22
###begin p 23
###xml 231 235 231 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Bell2">[39]</xref>
Detection of caspase cleaved cytokeratin-18 by flow cytometry was performed using Cytodeath reagent (Roche) according to the manufacturer's recommendations. Flow cytometric analysis of sub-G1 DNA content was performed as described [39].
###end p 23
###begin title 24
Plasmids
###end title 24
###begin p 25
###xml 44 48 44 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TAF6</italic>
###xml 134 166 134 166 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GGAGAAGAGGGACTCCAGAATGGCTG-3&#8242;</named-content>
###xml 181 210 181 210 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-TCCCCCAACCTTTGAGGCAGACG-3&#8242;</named-content>
###xml 336 338 336 338 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">II</sub>
###xml 346 350 342 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Bell2">[39]</xref>
To construct pASTAF6, the genomic region of TAF6 containing exon2 to exon4 was amplified by PCR from HEK 293 genomic DNA with primers 5'-GGAGAAGAGGGACTCCAGAATGGCTG-3' (forward) and 5'-TCCCCCAACCTTTGAGGCAGACG-3' (reverse). The resulting product was digested with HindIII and SmaI and inserted into the same sites of the plasmid pXJ42hTAFII80alpha [39].
###end p 25
###begin title 26
Antibodies
###end title 26
###begin p 27
###xml 85 89 77 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Bell2">[39]</xref>
###xml 101 105 93 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Brou1">[41]</xref>
###xml 122 126 114 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Dubrovskaya1">[42]</xref>
Monoclonal antibodies directed against TAF6delta (37TA-1 & 37TA-2), TAF6alpha (25TA) [39], TBP (3G3) [41], and TAF5 (2D2) [42] have been described. Monoclonal antibodies against TAF6 and PARP-1 were purchased from BD Transduction Laboratories and Biomol, respectively.
###end p 27
###begin title 28
Immunocytochemistry
###end title 28
###begin p 29
###xml 534 535 530 531 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 144 150 <span type="species:ncbi:9913">bovine</span>
###xml 403 407 <span type="species:ncbi:9925">goat</span>
###xml 413 418 <span type="species:ncbi:10090">mouse</span>
###xml 515 519 <span type="species:ncbi:9925">goat</span>
###xml 525 530 <span type="species:ncbi:10090">mouse</span>
Cells were fixed in 4% PFA, permeabilized with PBS-0.1% Triton X-100 (PBS-Tx) and incubated for 30 min in blocking buffer (PBS-Tx containing 1% bovine serum albumin (BSA) and 0.5% fish gelatine (Sigma-Aldrich)). Cells were then sequentially incubated one hour at room temperature, followed by washes, with each of the following antibodies diluted in blocking buffer; anti-TAF6 mAb (1/400), Oregon Green goat anti-mouse IgG secondary antibody (Molecular Probes), anti-TAF6delta mAb (37TA-1: 1/1000), Alexa Fluor 546 goat anti-mouse IgG1 secondary antibody (Molecular Probes). Cells were then treated with Hoechst 33342 (2 microg/ml) and visualized by fluorescence microscopy.
###end p 29
###begin title 30
Microarray Analysis of Gene Expression
###end title 30
###begin title 31
Transcriptome Acquisition
###end title 31
###begin p 32
###xml 517 525 513 521 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 33 38 <span type="species:ncbi:9606">Human</span>
###xml 198 203 <span type="species:ncbi:9606">human</span>
Total RNA was analyzed using ABI Human Whole Genome Survey Arrays v1.0 arrays (Prod. No.: 4359030), containing 31,700 60-mer oligonucleotide probes representing a set of 27,868 individual annotated human genes. Chemiluminescence detection technology is used to detect as little as a femtomole of expressed mRNA. One single round of linear amplification was performed from total RNA according to the Applied Biosystems RT-IVT (Applied Biosystems, ProdNo: 4339628) protocol using 2 microg of total RNA. cDNA synthesis, in vitro transcription and labeling, fragmentation, hybridization, staining, and scanning were performed as directed by the supplier (Applied Biosystems, ProdNo: 4346875).
###end p 32
###begin title 33
Transcriptome Data Analysis
###end title 33
###begin p 34
###xml 399 401 399 401 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sup>
###xml 482 483 482 483 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 761 762 761 762 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k</italic>
###xml 770 774 770 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Noth1">[43]</xref>
###xml 1026 1030 1026 1030 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Noth2">[44]</xref>
###xml 1237 1249 1233 1245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002721.s002">Data File S1</xref>
###xml 1326 1338 1318 1330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002721.s003">Data File S2</xref>
###xml 1536 1548 1524 1536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002721.s004">Data File S3</xref>
###xml 1670 1682 1654 1666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002721.s005">Data File S4</xref>
Applied Biosystems Expression Array System Software v1.1.1. (ProdNo: 4364137) has been used to acquire the chemiluminescence and fluorescence images and primary data analysis. We renormalized the resulting data according to the logarithmic signal median once more after having removed control probes and those probes for which the Applied Biosystems Software has set flags equal to or greater than 212, indicating compromised measurements (as recommended by Applied Biosystems). Log2 subtractions were determined using averages over the weighted individual signal values. The weights are anti-proportional to the corresponding coefficient of variation. For these inter-assay comparisons the NeONORM method was used for normalization using sensitivity parameter k = 0.20 [43]. P-values were determined using a standard ANOVA method. Multiple probes for a single gene, cross-reactivity of a single probe to several genes, as well as the resolution of probe-ID annotations were done according to the standards defined previously [44]. Gene lists corresponding to statistically significant changes in expression (P<0.05) are available as supplementary data files: genes changing in response TAF6delta in HCT-116 p53 +/+ cells (Supplementary Data File S1), genes changing in response to TAF6delta in HCT-116 p53 -/- (Supplementary Data File S2), genes differentially expressed in the HCT-116 p53 +/+ cells versus HCT-116 p53 -/- cells both in cells treated with control oligonucleotide and TAF6delta-inducing oligonucleotides (Supplementary Data File S3), and genes differentially regulated by TAF6delta in both HCT-116 p53 +/+ cells and HCT-116 p53 -/- cells (Supplementary Data File S4).
###end p 34
###begin p 35
The microarray data for the experiments described here were deposited in the Gene Expression Omnibus database () under accession number: GSE10795.
###end p 35
###begin p 36
The supplementary data files can also be accessed from the Benecke group webpage: .
###end p 36
###begin title 37
Real time PCR
###end title 37
###begin p 38
###xml 728 729 686 687 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</sub>
###xml 742 743 692 693 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</sub>
Real Time PCR was performed on cDNA prepared as for microarray experiments (above) using ABI TaqMan(R) assays. The genes and their respective assay numbers were ATF3 (Hs 00231069_m1), ACRC (Hs 00369516_m1), FNBP4 (Hs 00392543_m1) HES1 (Hs 00172878_m1), and HOM-TES-103 (Hs 00209961_m1). Real-time PCR was performed on 10 ng of cDNA with 1.25 microl of 20x TaqMan(R) probes and 12.5 microl 2x TaqMan(R) Universal Master Mix (ABI) in a final 25 microl reaction. Real-time PCR relative quantification assay was running for 2 min at 50degreesC, 10 min at 95degreesC, followed by 40 cycles of 15 sec at 95degreesC and 1 min at 60degreesC on an ABI 7500 system. Relative quantity of target genes was calculated using the comparative CT (DeltaDeltaCT) method using FNBP4 as the internal control.
###end p 38
###begin title 39
Results
###end title 39
###begin title 40
Selective induction of endogenous TAF6delta mRNA expression by splice-switching oligonucleotides
###end title 40
###begin p 41
###xml 99 103 84 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Weinzierl1">[31]</xref>
###xml 105 109 90 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Bell2">[39]</xref>
###xml 111 115 96 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Wang1">[45]</xref>
###xml 226 230 207 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Bell2">[39]</xref>
###xml 537 543 502 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002721-g001">Fig. 1</xref>
###xml 550 554 515 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TAF6</italic>
###xml 680 687 641 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002721-g001">Fig. 1A</xref>
###xml 816 823 769 776 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002721-g001">Fig. 1A</xref>
To date four splice variants of TAF6 have been identified and termed alpha, beta, gamma, and delta [31], [39], [45]. Here we focus on the TAF6delta splice variant due to its potentially important role in programmed cell death [39]. The total number of distinct TAF6 mRNA species produced by alternative splicing has not yet been established. For clarity, we therefore refer here collectively to all TAF6 splice variants lacking the 30 nucleotide exon IIalpha as TAF6delta and to TAF6alpha as all species of mRNA containing exon IIalpha (Fig. 1). The TAF6 genomic locus shows that the major TAF6alpha isoform is produced by the selection of an intron proximal 5' splice site (SS) (Fig. 1A). In contrast, the TAF6delta isoform is produced by an alternative splicing event at the intron distal 5' SS (labelled delta in Fig. 1A).
###end p 41
###begin title 42
Specific control of endogenous TAF6 alternative splicing by modified antisense RNA oligonucleotides in living cells.
###end title 42
###begin p 43
(A) The region of the TAF6 pre-mRNA that includes two alternative 5' splice sites (SSs) that produce either the constitutive alpha splice variant or the alternative delta splice variant is schematically depicted. Selection of an intron-proximal alpha 5' splice site (SS) results in production of the alpha isoform of TAF6 (at right) whereas the selection of the proximal delta 5' SS results in the production of the delta isoform (at left). The SSOs that base pair with the alternative exon forces splicing from the distal 5' SS and induces expression of the endogenous TAF6delta isoform (at left). The protein produced by the major splice variant, TAF6alpha, can interact with the TFIID subunit, TAF9 via its histone fold domain. In contrast, TAF6delta lacks 10 amino acids of helix 2 of its histone fold motif and therefore cannot interact with TAF9. (B) Antisense RNA oligonucleotides induce endogenous TAF6delta mRNA expression. HeLa cells were transfected with 200 nM oligonucleotides directed against: the alternative exon II (exon IIalpha) of the TAF6 gene (Taf6 AS1), the Bcl-x gene (Bcl-x AS), or a scrambled control oligonucleotide (Control AS). 24 hours post-transfection total RNA was isolated and subjected to RT-PCR with primers that amplify both the TAF6alpha and the alternative TAF6delta mRNAs. (C) Specificity of TAF6 splice site switching oligonucleotides. HeLa cells were transfected with antisense RNA oligonucleotides as in A. RT-PCR was perfomed with primers sets that amplify the both the alpha and delta TAF6 splice variants, or both the Bcl-xS and Bcl-xL splice variants. PCR products were separated by microfluidity and analyzed using a 2100 Agilent bioanalyzer. The ratio of TAF6delta mRNA over total TAF6 mRNA and the ratio of Bcl-Xs mRNA over total Bcl-X mRNA are expressed on the y-axis. The values from cells treated with scrambled control (grey bars), Taf6 AS1 (black bars), or Bcl-X AS (white bars) are shown. Error bars represent the standard deviation of three independent transfections.
###end p 43
###begin p 44
###xml 69 70 65 66 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">s</underline>
###xml 76 77 72 73 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">s</underline>
###xml 86 87 82 83 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">o</underline>
###xml 110 114 106 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Mercatante1">[40]</xref>
###xml 116 120 112 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Taylor1">[46]</xref>
###xml 357 361 345 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Bell2">[39]</xref>
###xml 407 408 395 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">O</italic>
###xml 537 544 521 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002721-g001">Fig. 1A</xref>
###xml 893 900 861 868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002721-g001">Fig. 1B</xref>
###xml 1034 1041 994 1001 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002721-g001">Fig. 1B</xref>
###xml 1211 1215 1171 1175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Mercatante1">[40]</xref>
###xml 1387 1394 1323 1330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002721-g001">Fig. 1C</xref>
###xml 1518 1525 1442 1449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002721-g001">Fig. 1C</xref>
To dissect the biological role of endogenous TAF6delta, we exploited splice-switching oligonucleotides (SSOs) [40], [46] to experimentally manipulate endogenous TAF6 alternative splicing. The HeLa cell system represents a natural cellular context to study TAF6delta function because the TAF6delta variant was originally cloned from a HeLa cell cDNA library [39]. We transfected HeLa cells with synthetic 2'-O-methyl-modified oligoribonucleoside phosphorothioate that hybridizes to the central 20 nucleotides of alternative exon IIalpha (Fig. 1A). The ratio of the alternative TAF6delta mRNA level with respect to TAF6alpha mRNA level was analyzed by RT-PCR of RNA samples from transfected HeLa cells. The transfection of the antisense oligonucleotide Taf6 AS1 resulted in a marked increase in the level of the TAF6delta mRNA and a concurrent decrease in the level of the major TAF6alpha mRNA (Fig. 1B, lane 3). In contrast, transfection of an oligonucleotide of scrambled sequence had no effect on the TAF6delta/TAF6alpha mRNA ratio (Fig. 1B, lane 2). To further demonstrate the specificity of the SSOs, we transfected antisense RNA oligonucleotides shown to enforce the expression of the Bcl-xS splice variant [40]. The TAF6delta/TAF6alpha+delta mRNA ratio was increased approximately3-fold by treatment with the Taf6 AS1 oligonucleotide, but unchanged by the Bcl-x AS oligonucleotide (Fig. 1C). Conversely the ratio of Bcl-xS/Bcl-xL+xS mRNA was increased approximately10-fold by Bcl-x AS but unaffected by Taf6 AS1 (Fig. 1C). Control RT-PCR reactions showed that ratio of TAF6delta with respect to total TAF6 mRNA is increased by Taf6 SSO but none of the ratios of any other known TAF6 alternative splice variants was affected (data not shown). The SSOs used therefore impact specifically on TAF6delta alternative splicing without influencing overall expression patterns of TAF6 mRNA. These results demonstrate that TAF6-directed SSOs are an efficient and selective method to enforce the expression of the endogenous TAF6delta mRNA in HeLa cells.
###end p 44
###begin p 45
###xml 250 258 246 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002721.s001">Fig. S1A</xref>
###xml 337 341 333 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Mercatante1">[40]</xref>
###xml 775 783 763 771 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002721.s001">Fig. S1B</xref>
To further characterize the cellular response to TAF6 splice site switching antisense oligonucleotides we performed a time course analysis. The level of TAF6delta mRNA is detectably increased after 4 hours and increases until 24 hours (Supplementary Fig. S1A). These results are consistent with a previous study targeting the Bcl-x gene [40], and establish a kinetic framework to follow the early outcomes of TAF6delta mRNA expression in transfected cells. We next investigated the concentration dependence for the Taf6 response to treatment with the AS1 oligonucleotide. The induction of TAF6delta mRNA was observed with transfection of as little as 50 nM Taf6 AS1 and sharply increased until treatment with 200 nM Taf6 AS1, after which a plateau was reached (Supplementary Fig. S1B). Based on these results, we have employed 200 nM oligonucleotide concentrations herein, unless otherwise stated, for robust and specific induction of endogenous TAF6delta mRNA in living cells.
###end p 45
###begin title 46
Splice-switching oligonucleotides increase endogenous TAF6delta protein levels
###end title 46
###begin p 47
###xml 394 401 386 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002721-g002">Fig. 2A</xref>
###xml 534 541 522 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002721-g002">Fig. 2A</xref>
###xml 737 741 717 721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Bell2">[39]</xref>
###xml 899 906 875 882 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002721-g002">Fig. 2A</xref>
###xml 1048 1055 1020 1027 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002721-g002">Fig. 2A</xref>
###xml 1378 1385 1330 1337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002721-g002">Fig. 2B</xref>
###xml 1538 1545 1486 1493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002721-g002">Fig. 2B</xref>
We next investigated the influence of the splice site switching oligonucleotides on the levels of TAF6delta and TAF6alpha proteins. TAF6 was detected by immunocytochemistry using monoclonal antibodies that recognize an epitope present in all of the known isoforms of TAF6. HeLa cells treated with negative control oligonucleotides showed strong TAF6 staining throughout the entire nucleoplasm (Fig. 2A). The nuclear total TAF6 immunofluorescent signal is diminished in cells treated with SSOs that increase TAF6delta mRNA production (Fig. 2A), presumably due to decreased expression of TAF6alpha (see also below). TAF6delta was detected by immunofluorescence with monoclonal antibodies that specifically recognize the delta TAF6 isoform [39]. HeLa cells transfected with negative control antisense oligonucleotides exhibited undetectable cellular staining with anti-TAF6delta monoclonal antibodies (Fig. 2A). In contrast, transfection of HeLa cells with oligonucleotides that induce TAF6delta mRNA expression resulted in punctate nuclear staining (Fig. 2A). We further quantified the influence of antisense treatment by scoring the number of cells displaying clear nuclear TAF6delta immunofluorescent signals. We found that treatment with the Taf6 AS1 oligonucleotide resulted in nearly approximately10 fold more cells with TAF6delta staining compared to control treated cells (Fig. 2B). As a further control of specificity, oligonucleotide Bcl-x AS was transfected and caused no increase in nuclear TAF6delta immunofluorescent staining (Fig. 2B). We conclude that TAF6delta protein in discrete nuclear loci is significantly increased by SSO targeting of the TAF6 pre-mRNA.
###end p 47
###begin title 48
Specific induction of TAF6delta protein expression by modified antisense RNA oligonucleotides.
###end title 48
###begin p 49
(A) HeLa cells were transfected with splice site-switching oligonucleotides directed against exon IIalpha of the TAF6 gene and treated with MG-132 5 hours later. 21 hours post transfection cells were fixed and stained with the indicated antibodies for immunocytochemistry (B) Quantification of endogenous TAF6delta expressing cells transfected with splice site-switching antisense oligonucleotides. Results are expressed as the percentage of cells displaying a clear TAF6delta punctate staining on a total of at least 500 cells. (C) Translation of exogenous TAF6delta is induced by modified antisense RNA oligonucleotides. Schematic representation of plasmid pASTAF6 containing sequences derived from the TAF6 cDNA (white) or from genomic DNA (grey). HeLa cells were first transfected with pASTAF6 and 19 hours later with splice site switching oligonucleotides and treated with MG132 and ZVAD-FMK 6 hours after this second transfection. 38 hours post-transfection protein extracts from cells were analyzed by immunoblotting with monoclonal antibodies directed against TFIID subunits.
###end p 49
###begin p 50
###xml 590 594 578 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Bell2">[39]</xref>
###xml 621 625 609 613 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TAF6</italic>
###xml 679 686 667 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002721-g002">Fig. 2C</xref>
###xml 957 964 933 940 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002721-g002">Fig. 2C</xref>
Immunofluorescence experiments measure the levels of detectable antigen in fixed cells. Since the levels of total cellular protein can potentially differ from the antigenically recognizable levels of protein we employed immunoblotting under denaturing conditions to directly examine the effect of TAF6delta-inducing oligonucleotides on the translation of the TAF6delta mRNA in treated cells. Endogenous TAF6delta is undetectable by Western blotting of extracts from HeLa cell due to its rapid turnover by the proteasome (data not shown) and by caspase-dependent cleavage in apoptotic cells [39]. We therefore developed a TAF6 minigene plasmid that is responsive to SSO (pASTAF6, Fig. 2C). Immunoblots on total protein extracts from HeLa cells transfected with the spliceable minigene construct and later treated with TAF6delta-inducing oligonucleotides resulted in a marked increase in TAF6delta protein levels, with a corresponding reduction in TAF6alpha (Fig. 2C). The levels of two other TFIID subunits, TAF5 and TBP, remained relatively constant. These data demonstrate a selective induction of TAF6delta translation and concomitant reduction in TAF6alpha levels by TAF6delta-inducing SSOs.
###end p 50
###begin title 51
Endogenous TAF6delta expression causes apoptosis in HeLa cells
###end title 51
###begin p 52
###xml 296 303 292 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002721-g003">Fig. 3A</xref>
###xml 527 534 519 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002721-g003">Fig. 3A</xref>
###xml 880 887 864 871 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002721-g003">Fig. 3B</xref>
###xml 1041 1045 1025 1029 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Mercatante2">[47]</xref>
###xml 1128 1135 1112 1119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002721-g003">Fig. 3B</xref>
###xml 1344 1348 1324 1328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Leers1">[48]</xref>
###xml 1466 1473 1446 1453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002721-g003">Fig. 3C</xref>
###xml 1767 1774 1743 1750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002721-g003">Fig. 3D</xref>
We next investigated the physiological consequences of SSO-induced endogenous TAF6delta expression in HeLa cells. The transfection of HeLa cells with a scrambled antisense oligonucleotide resulted in no obvious morphological changes or changes in cell number when visualized by light microscopy (Fig. 3A, left image). In stark contrast, TAF6delta-inducing SSO resulted in an obvious loss of adherent cells and produced significant numbers of cells that exhibit the classical features of apoptosis, including membrane blebbing (Fig. 3A, right image). To obtain further evidence that TAF6delta induction causes apoptosis we measured cleavage of the well-known caspase substrate PARP-1, since activation of the caspase protease cascade is a defining biochemical feature of apoptosis. Immunoblotting revealed readily detectable cleavage of PARP-1 in cells when TAF6delta was induced (Fig. 3B, lane 2). As an additional control for the specificity of the Taf6 AS1 oligonucleotide, we used a Bcl-xS-inducing SSO. Consistent with a previous report [47], the induction of Bcl-xS expression has little effect on apoptosis in HeLa cells (Fig. 3B, lane 3). To further substantiate and quantify TAF6delta-induced apoptosis we employed flow cytometry to measure the levels of caspase-cleaved cytokeratin-18 (KRT18c), another established marker of apoptosis [48]. Treatment of HeLa cells with the Taf6 AS1 oligonucleotide resulted in a 3.5 fold increase in KRT18c positive cells (Fig. 3C). As an independent quantification of apoptosis, we employed flow cytometry to measure the level of Sub-G1 DNA content. This assay showed that TAF6delta induction resulted in a 2.8 fold increase in apoptosis whereas Bcl-xS induction resulted in a 1.3 fold increase in apoptosis in HeLa cells (Fig. 3D). Thus, four distinct assays show that the induction of endogenous TAF6delta triggers a robust apoptotic response in HeLa cells.
###end p 52
###begin title 53
Expression of endogenous TAF6delta causes cell death by apoptosis.
###end title 53
###begin p 54
HeLa cells were transfected with antisense oligonucleotides that induce endogenous TAF6delta (Taf6 AS1), scrambled control oligonucleotides (Control AS), or oligonucleotides that induce endogenous Bcl-xS expression (Bcl-x AS). (A) 24 hours post transfection cells were observed by differential interference contrast microscopy. (B) Proteins were extracted from transfected cells and subjected to immunoblot analysis with anti-PARP monoclonal antibodies. PARPc indicates caspase cleaved PARP. (C) The percentage of apoptotic cells was analyzed by flow cytometry using monoclonal antibodies that detect caspase cleaved cytokeratin-18. (D) The percentage of apoptotic cells was analyzed by flow cytometry to detect sub G1 DNA content. The values indicated above the data bars are the fold induction of apoptosis with respect to Control oligonucleotide-treated cells.
###end p 54
###begin title 55
TAF6delta induces apoptosis in the absence of p53
###end title 55
###begin p 56
###xml 83 95 79 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s1">Introduction</xref>
###xml 231 234 227 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Vousden1">[6]</xref>
###xml 503 506 491 494 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 512 516 500 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Masuda1">[49]</xref>
###xml 665 672 649 656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002721-g004">Fig. 4A</xref>
###xml 813 820 773 780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002721-g004">Fig. 4B</xref>
###xml 937 944 893 900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002721-g004">Fig. 4C</xref>
###xml 1178 1182 1134 1138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-May1">[50]</xref>
###xml 1366 1373 1322 1329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002721-g004">Fig. 4D</xref>
###xml 1462 1469 1418 1425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002721-g004">Fig. 4D</xref>
###xml 1647 1654 1599 1606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002721-g004">Fig. 4E</xref>
###xml 1914 1918 1862 1866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Bunz1">[51]</xref>
###xml 2110 2117 2054 2061 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002721-g005">Fig. 5B</xref>
###xml 2143 2150 2087 2094 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002721-g005">Fig. 5C</xref>
###xml 2250 2257 2190 2197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002721-g005">Fig. 5A</xref>
###xml 148 153 <span type="species:ncbi:9606">human</span>
###xml 1140 1161 <span type="species:ncbi:10566">Human Papilloma Virus</span>
###xml 1770 1775 <span type="species:ncbi:9606">human</span>
The tumor suppressor p53 interacts physically and functionally with TAF6alpha (see Introduction). Mutations in the p53 pathway are thought to allow human tumor cells to escape apoptotic death and therefore allow cancer development [6]. It was therefore of fundamental importance to establish whether TAF6delta-induced apoptosis can occur in the absence of p53. To address whether TAF6delta-dependent apoptosis requires p53 we transfected the Saos-2 osteosarcoma cell line that is devoid of a functional p53 gene [49] with oligonucleotide Taf6 AS1. Transfection of Taf6 AS1, but not Bcl-x AS into Saos-2 cells effectively increased endogenous TAF6delta mRNA levels (Fig. 4A, lane 3). Analysis of the RT-PCR results showed an approximately approximately5 fold induction in the TAF6delta/TAF6alpha+delta mRNA ratio (Fig. 4B). The expression of TAF6delta induced a 3.3 fold increase in apoptosis in Saos-2 as measured by Sub-G1 DNA content (Fig. 4C). Similar results were obtained in another cell line (H1299 lung carcinoma) that does not contain p53 (data not shown). Because HeLa cells have impaired p53 function due to the expression of the Human Papilloma Virus E6 gene product [50], we also compared the efficiency of induction of apoptosis in the A549 lung carcinoma cells because they express wild type p53. Taf6 AS1 transfection increased apoptosis by 3.1 fold (Fig. 4D), whereas Bcl-x AS transfection caused no increase in apoptosis over background levels (Fig. 4D). The fact that Saos-2 are at least as susceptible as A549 cells to TAF6delta-induced programmed cell death was further verified by measuring PARP-1 cleavage by immunoblotting (Fig. 4E versus 4F). To reinforce the fact that p53 is dispensable for TAF6delta-induced apoptosis, we employed the HCT-116 human colon carcinoma cell line and its isogenic counterpart HCT-116 p53 -/- in which the p53 gene has been deleted by homologous recombination [51]. The induction of apoptosis by TAF6delta in isogenic cells lacking p53 is equally robust as in wild-type cells, as judged by significant increases in both caspase-cleavage of cytokeratin-18 (Fig. 5B) and Sub-G1 DNA content (Fig. 5C). The induction of TAF6delta protein levels by the SSO strategy was efficient in both cells lines (Fig. 5A). The results demonstrate that p53 is dispensable for TAF6delta-induced cell death. We conclude that TAF6delta controls apoptosis irrespective of cellular p53 status.
###end p 56
###begin title 57
TAF6delta induces apoptosis in cancer cell lines lacking p53.
###end title 57
###begin p 58
###xml 7 12 <span type="species:ncbi:9606">human</span>
###xml 772 777 <span type="species:ncbi:9606">human</span>
Saos-2 human bone osteosarcoma cells, that do not express p53, were transfected with antisense oligonucleotides that induce endogenous TAF6delta (Taf6 AS1), scrambled control oligonucleotides (Control AS), or oligonucleotides that induce endogenous Bcl-xS expression (Bcl-x AS). (A) 24 hours post transfection total RNA was isolated for analysis by RT-PCR with primers that amplify both the TAF6alpha and TAF6delta mRNAs. (B) RT-PCR products were analyzed on an Agilent Bioanalyzer. Error bars indicate the standard deviation of three independent transfections. (C) Percentage of apoptotic Saos-2 cells was analyzed by flow cytometry to detect sub G1 DNA content. Error bars indicate the standard deviation of three independent transfections. (D) As in C except that A549 human lung carcinoma cells, that express wild-type p53, were transfected. (E) As in C except that proteins were extracted from transfected Saos-2 cells and subjected to immunoblot analysis with anti-PARP monoclonal antibodies. PARPc indicates caspase cleaved PARP. (F) As in E except with A549 cells.
###end p 58
###begin title 59
p53 is dispensable for TAF6delta-induced apoptosis.
###end title 59
###begin p 60
###xml 211 218 211 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002721-g002">Fig. 2C</xref>
(A) Western blot analysis of TFIID subunits following TAF6 and Bcl-x SSO in HCT-116 p53 +/+ (left panels) and HCT-116 p53 -/- cells (right panels). HCT-116 cells were transfected first with plasmid pASTAF6 (see Fig. 2C) and 19 hours later with antisense oligonucleotides that induce endogenous TAF6delta (Taf6 AS1), scrambled control oligonucleotides (Control AS), or oligonucleotides that induce endogenous Bcl-xS expression (Bcl-x AS). Total cells extracts were prepared and separated on 10% SDS-PAGE, followed by immunoblotting with anti-TFIID subunit antibodies as indicated with arrows. (B) The percentage of apoptotic cells was analyzed by flow cytometry using monoclonal antibodies that detect caspase cleaved cytokeratin-18. (C) The percentage of apoptotic cells was analyzed by flow cytometry to detect sub G1 DNA content. The values indicated above the data bars are the fold induction of apoptosis with respect to Control oligonucleotide-treated cells. Error bars indicate the standard deviation of three independent transfections.
###end p 60
###begin title 61
TAF6delta activates gene expression independently of p53
###end title 61
###begin p 62
###xml 187 195 179 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 280 287 271 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 287 291 278 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Bell2">[39]</xref>
###xml 293 297 284 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TAF6</italic>
###xml 392 404 383 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s1">Introduction</xref>
###xml 744 751 723 730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002721-g002">Fig. 2B</xref>
###xml 851 857 826 832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002721-g003">Fig. 3</xref>
###xml 1178 1182 1153 1157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Noth3">[52]</xref>
###xml 1184 1188 1159 1163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Wang2">[53]</xref>
###xml 1251 1271 1226 1246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s2">Material and Methods</xref>
###xml 1238 1243 <span type="species:ncbi:9606">human</span>
TAF6delta can induce apoptosis of several cancer cell lines independent of their p53 status. We have previously shown that TAF6delta can bind the TFIID subunits TAF1, TAF5, TBP and TAF12 in vitro, and forms a TFIID-like complex that contains several TAFs but lacks TAF9 (TFIIDpi) in vivo[39]. TAF6 is an essential gene that plays a broad role in the regulation of transcription programs (see Introduction). To investigate whether TAF6delta can regulate transcription, with an emphasis on potentially p53-independent transcription, we employed genome-wide microarray technology. The transcriptional effects of TAF6delta are technically difficult to measure because endogenous TAF6delta is not induced in all cells during antisense transfection (Fig. 2B) and because endogenous TAF6delta-expressing cells are lost rapidly from the culture by apoptosis (Fig. 3). In order to achieve maximal sensitivity we chose a recently developed microarray technology based on chemiluminescent detection and longer oligonucleotide probes (60 nucleotides), that has been shown to provide increased signal dynamic range and higher sensitivity when compared to traditional microarray technologies [52], [53]. The microarrays used represent 27,868 annotated human genes (Material and Methods).
###end p 62
###begin p 63
###xml 770 791 766 787 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s2">Materials and Methods</xref>
The design of the microarray experiments enables detection of direct TAF6delta target genes without excluding potentially informative rapid secondary changes in mRNA levels. Wild-type HCT-116 and their p53-null isogenic counterparts (HCT-116 p53 -/-) were transfected with oligonucleotides Taf6 AS2 and Control AS, and total RNA was isolated and subjected to microarray analysis after 24 hours. The scrambled control oligonucleotide was employed as a reference to exclude any non-specific changes in gene expression due to the transfection protocol or the introduction of exogenous oligonucleotide into cells. Biological triplicates (three independent transfections) were performed for each condition and statistical analysis and filtering was performed, as detailed in Materials and Methods, to identify significantly (P<0.05) regulated mRNAs.
###end p 63
###begin p 64
###xml 200 207 196 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002721-g006">Fig. 6A</xref>
The induction of endogenous TAF6delta in wild-type HCT-116 cells resulted in significant changes in the levels of 321 mRNAs out of a total of 27,868 independent genes measured by microarray analysis (Fig. 6A). The induction of endogenous TAF6delta in HCT-116 lacking p53 expression resulted in significant changes in the levels of 444 mRNAs. In both cells the majority of mRNAs are increased in response to TAF6delta. These data establish that TAF6delta acts primarily as a positive regulator of gene expression and rule out the possibility that TAF6delta-induced cell death is a result of a global reduction in mRNA transcription.
###end p 64
###begin title 65
Endogenous TAF6delta expression induces apoptosis in the absence of p53.
###end title 65
###begin p 66
(A) Transcriptome analysis following TAF6 SSO in HCT-116 p53+/+ and p53-/- cells. Expression levels of mRNAs from cells treated with oligonucleotide Taf6AS2 were individually compared to control oligonucleotide-treated HCT-116 samples by genome-wide microarray analysis. The absolute number of probes detecting statistically significant (p<0.05) up- or down-regulation following splice-site selection is shown to the left of each bar; the maximum positive or negative logarithmic (base two) fold-change is shown to the right. The red gradient indicates positive, and the blue gradient negative fold changes in expression. (B) Transcriptome analysis following TAF6 SSO in HCT-116 cells and selecting for those genes that show significant regulation between the HCT-116 p53 +/+ versus HCT-116 p53 -/- cells irrespective of TAF6delta expression. Labels as in (A). (C) Venn-Diagram displaying the overlap between the three different target gene repertoires shown in (A) and (B). (D) Verification of gene expression changes by quantitative real-time RT-PCR. HCT-116 p53+/+ and HCT-116 p53-/- cells were transfected with two distinct antisense oligonucleotides that induce endogenous TAF6delta; Taf6 AS1 (grey bars), Taf6 AS2 (black bars). White bars indicate values from microarray experiments for comparison. 18 hours post-transfection total RNA was extracted and the levels of the indicated mRNAs were analyzed by quantitative real-time PCR with respect to the levels from cells treated with the control oligonucleotide. Error bars indicate standard deviation of three independent transfections.
###end p 66
###begin p 67
###xml 40 44 36 40 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Thut1">[34]</xref>
###xml 442 449 430 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002721-g006">Fig. 6B</xref>
###xml 514 518 502 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-OwenSchaub1">[54]</xref>
###xml 525 528 513 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Hwang1">[8]</xref>
###xml 536 540 524 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Kunz1">[55]</xref>
###xml 556 560 544 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-elDeiry1">[56]</xref>
###xml 617 629 605 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002721.s004">Data File S3</xref>
###xml 1075 1082 1059 1066 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002721-g006">Fig. 6C</xref>
###xml 1643 1650 1615 1622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002721-g001">Fig. 1C</xref>
###xml 1682 1689 1654 1661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002721-g002">Fig. 2B</xref>
###xml 1774 1781 1742 1749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002721-g006">Fig. 6C</xref>
###xml 2252 2259 2212 2219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002721-g006">Fig. 6D</xref>
###xml 2543 2550 2499 2506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002721-g006">Fig. 6D</xref>
###xml 2737 2744 2689 2696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002721-g006">Fig. 6D</xref>
TAF6alpha physically interacts with p53 [34], yet TAF6delta induces apoptosis in cells lacking p53. We therefore analyzed the microarray data to determine whether TAF6delta can control gene expression independently of p53. The p53-dependent genes were identified by filtering for genes that are significantly changed in the wild-type HCT-116 versus HCT-116 p53 -/- in both the presence of the TAF6 SSO or a scrambled control oligonucleotide (Fig. 6B). As expected, well-established p53 target genes, including FAS [54], FDXR [8], SESN1 [55] and p21/CDKN1A [56] were found in the p53-dependent gene set (Supplementary Data File S3), confirming the sensitivity and accuracy of the microarray methodology. We focused on the identification of genes regulated in both wild-type HCT-116 and HCT-116 p53 -/- because these mRNAs represent candidates for genes that function to induce p53-independent apoptosis. The different gene sets significantly regulated by TAF6delta in wild-type and p53 negative HCT-116 cells, as well as the p53-dependent genes, are shown by Venn diagrams in Fig. 6C. The absolute numbers of TAF6delta-dependent genes is underestimated when compared to p53-dependent genes because the two gene sets are derived from very technically different approaches. p53-dependence is defined here through the use of an isogenic cell line in which p53 expression is eliminated completely in 100% of cells by genetic ablation through homologous recombination. In contrast TAF6delta-dependency is defined by the induction of endogenous TAF6delta via transient transfection with splice switching oligonucleotides, that occurs only partially (Fig. 1C) and in fraction of the cells (Fig. 2B). Nonetheless, the analysis revealed 21 TAF6delta-dependent, p53-independent genes (Fig. 6C). To independently validate the TAF6delta-dependent genes we selected 4 genes (and the internal control FNBP4) for real-time quantitative RT-PCR analysis. One gene (HOM-TES-103) is within our P-value cut-of (P<0.05), another (ACRC) is slightly outside the P-value cut-off (P = 0.0698), and a third (HES1) substantially outside our cutoff (P = 0.2012). ACRC, HES1 and HOM-TES-103 were induced by TAF6delta in wild-type p53 HCT-116 cells as well as HCT-116 p53 -/- cells (Fig. 6D). We also verified the expression of ATF3, since it represents the distinct class of genes that are regulated by TAF6delta only in the presence of p53. ATF3 induction was documented in HCT-116 cells expressing p53 but not in p53-null HCT-116 cells, as validated by real-time RT-PCR (Fig. 6D). To reinforce the specificity of all of these effects, we employed two distinct TAF6delta-inducing SSOs, both of which caused comparable changes in expression of the four genes tested (Fig. 6D). These results confirm that TAF6delta can induce gene expression independently of the tumor suppressor p53.
###end p 67
###begin title 68
Discussion
###end title 68
###begin p 69
###xml 22 23 22 23 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">s</underline>
###xml 29 30 29 30 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">s</underline>
###xml 39 40 39 40 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">o</underline>
Here we have combined splice-switching oligonucleotides (SSOs) with high-sensitivity genome-wide microarrays to shed light on the function of endogenous TAF6delta. By experimentally inducing endogenous TAF6delta expression we show that TAF6delta triggers robust cell death in several cancer cell types. The expression of the p53 tumor suppressor is dispensable for TAF6delta-dependent cell death and gene expression in several cell lines. The data establish the TAF6delta pathway as an important signaling hub that can control apoptosis in the absence of p53. Our microarray results show that TAF6delta expression activates genes, such as HOM-TES-103, HES1 and ACRC independently of p53. The 21 genes we identify here that are controlled by TAF6delta independently of p53 represent candidate genes that could mediate TAF6delta-dependent apoptosis. The majority of genes identified through the unbiased microarray approach are of as yet unknown biological function; a finding that is not unexpected given that TAF6delta represents a newly discovered signaling pathway. Therefore, further work will be required to determine their contributions to the apoptotic program. Given the fact that TAF6delta activates minimally hundreds of genes, it is improbable that any single gene product could account fully for TAF6delta-driven apoptosis. The microarray data presented here represent, to our knowledge, the first documentation of changes in gene expression due to induction of an endogenous TFIID subunit. Based on the increases in gene expression we have demonstrated here, we propose a model in which TAF6delta drives a pro-apoptotic transcription program to initiate the apoptotic cascade.
###end p 69
###begin p 70
###xml 761 765 741 745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Bell2">[39]</xref>
Despite intensive efforts, the molecular mechanisms by which the TAFs specifically influence gene expression remain obscure. The advantage of the SSO strategy employed here is that it reveals for the first time a pro-apoptotic role for endogenous TAF6delta levels. As is the case for all physiological alternative splicing events, the TAF6delta isoform is produced with a concomitant reduction in the levels of the major alpha isoform. The reduction in TAF6alpha may contribute to changes in gene expression during the SSO-enforced as well as the normal physiological switch from alpha to delta expression. It is, however, important to note that the overexpression of TAF6delta alone is sufficient to induce apoptosis in cells that express endogenous TAF6alpha [39]. Therefore, although decreased TAF6alpha expression necessarily accompanies increased TAF6delta expression, all the available evidence indicates that the increase of the minor TAF6delta isoform is a critical molecular event triggering apoptosis.
###end p 70
###begin p 71
###xml 75 79 75 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Muller2">[57]</xref>
###xml 119 123 119 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Gegonne1">[58]</xref>
###xml 193 200 193 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 361 365 361 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Deato1">[59]</xref>
###xml 583 587 583 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Mengus1">[60]</xref>
###xml 671 675 671 675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Frontini1">[61]</xref>
###xml 770 774 770 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Katzenberger1">[62]</xref>
###xml 776 780 776 780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Metcalf1">[63]</xref>
###xml 1272 1276 1264 1268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Bell2">[39]</xref>
###xml 1373 1377 1365 1369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Robles1">[64]</xref>
Mounting evidence suggests that functionally distinct forms of TFIID exist [57], and that TFIID composition is dynamic [58]. Recently, the dynamic nature of core promoter recognition complexes in vivo has been underscored by the observation of a drastic replacement of the cellular pools of canonical TFIID with a complex containing TRF3/TAF3 during myogenesis [59]. The number of combinatorial possibilities for more subtle changes within the TFIID complex itself continues to expand with the discovery of new TAF isoforms; TAF4 and TAF4b possess distinct target gene specificities [60], TAF9 and TAF9b can both incorporate into TFIID but are functionally non-redundant [61], and TAF1-2 and TAF1-4 are signal-inducible and functionally distinct splice variants of TAF1 [62], [63]. To date, however, the functional consequences for changes in the cellular levels of endogenous TFIID subunits have remained unknown. The current findings show that the induction of a single TFIID subunit within living cells can orchestrate gene expression programs to alter cell physiology. TAF6delta mRNA levels can be dramatically induced in HL-60 cells after differentiation by retinoic-acid, demonstrating at least one physiological situation where TAF6delta is induced in living cells [39]. Recent genetic evidence that TAF12 is required for ethylene-responsive transcription in plants [64] further argues that TFIID is a signal-responsive transcription factor. Therefore, in addition to its known functions in core promoter recognition and co-activation, TFIID represents a platform that integrates cellular signals with the control of gene expression.
###end p 71
###begin p 72
###xml 216 219 216 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Vousden1">[6]</xref>
###xml 363 366 363 366 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARF</sup>
###xml 363 366 363 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sup>ARF</sup></italic>
###xml 381 385 381 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Martins1">[65]</xref>
###xml 483 487 483 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TAF6</italic>
###xml 857 864 849 856 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002721-g006">Fig. 6B</xref>
###xml 936 940 928 932 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Poon1">[26]</xref>
###xml 942 946 934 938 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Lago1">[27]</xref>
###xml 948 952 940 944 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Aoyagi1">[28]</xref>
###xml 954 958 946 950 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Amsterdam1">[29]</xref>
###xml 983 987 975 979 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TAF6</italic>
###xml 1085 1090 1077 1082 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcl-x</italic>
###xml 1120 1127 1112 1119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002721-g003">Fig.s 3</xref>
###xml 1129 1130 1121 1122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002721-g004">4</xref>
###xml 1133 1134 1125 1126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002721-g005">5</xref>
The pro-apoptotic transcription factor p53 plays a central role in genome surveillance and tumor suppression. The p53 protein is not required for cell viability and indeed is lost or mutated in roughly 50% of tumors [6]. Even in animal models where functional p53 can be restored by gene therapy, tumors readily attain resistance to p53 due to inactivation of p19ARF or p53 itself [65]. The efficient induction of cell death in several different tumor cell lines by SSO targeting of TAF6, independent of their p53 status, provides a proof-of-principle that the TAF6delta pathway can be exploited to kill tumor cells. The data presented here define the TAF6delta signaling hub as able to control apoptosis without p53, but with interconnections to the p53 pathway including several shared target genes, as revealed by transcriptome-wide microarray analysis (Fig. 6B). Unlike p53, TAF6 is essential for viability in all organisms studied [26], [27], [28], [29]. Furthermore, targeting TAF6 results in a substantially more robust apoptotic response than targeting another apoptotic gene, Bcl-x in several tumor cell lines (Fig.s 3, 4 & 5). Further characterization of the TAF6delta signaling hub may therefore provide novel therapeutic avenues to induce controlled tumor cell death irrespective of their p53 status.
###end p 72
###begin p 73
###xml 569 573 553 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Dressman1">[66]</xref>
###xml 669 673 653 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002721-Wang1">[45]</xref>
###xml 754 761 734 741 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 314 319 <span type="species:ncbi:9606">human</span>
The TAF6delta pathway remains an orphan pathway since the precise molecular trigger that induces TAF6delta expression in the physiological context is currently unknown. The fact that TAF6delta can act downstream of p53 to control gene expression, and that TAF6delta can dictate cell death versus life decisions of human cells, evoke the possibility that this newly defined pathway could be subject to deregulation in certain cancer cells. In this light, it is intriguing that expression levels of TAF6 have been correlated with the inflammatory breast cancer phenotype [66], and isoform specific enrichment of a TAF6 splicing variant has been reported in breast cancer [45]. Experiments to identify the upstream signals that control TAF6delta expression in vivo in healthy tissues, as well as to uncover the potential role of mutations to the TAF6delta pathway in cancer are ongoing in our laboratory.
###end p 73
###begin title 74
Supporting Information
###end title 74
###begin p 75
###xml 115 122 111 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002721-g001">Fig. 1C</xref>
(A) Time course for antisense RNA-mediated TAF6delta mRNA induction. Transfections and RT-PCR were performed as in Fig. 1C except that RNA was extracted at various times (x-axis) after transfection. (B) Dose-dependent antisense mediated induction of TAF6delta mRNA expression. As in B, with different concentrations of oligonucleotides transfected indicated on the x-axis.
###end p 75
###begin p 76
(0.71 MB EPS)
###end p 76
###begin p 77
Click here for additional data file.
###end p 77
###begin p 78
Genes changing in response TAF6delta in HCT-116 p53 +/+ cells
###end p 78
###begin p 79
(0.05 MB TXT)
###end p 79
###begin p 80
Click here for additional data file.
###end p 80
###begin p 81
Genes changing in response to TAF6delta in HCT-116 p53 -/-
###end p 81
###begin p 82
(0.07 MB TXT)
###end p 82
###begin p 83
Click here for additional data file.
###end p 83
###begin p 84
Genes differentially expressed in the HCT-116 p53 +/+ cells versus in HCT-116 p53 -/- cells both in cells treated with control oligonucleotide and TAF6delta -inducing oligonucleotides
###end p 84
###begin p 85
(0.24 MB TXT)
###end p 85
###begin p 86
Click here for additional data file.
###end p 86
###begin p 87
Genes differentially regulated by TAF6delta in both HCT-116 p53 +/+ cells and HCT-116 p53 -/- cells
###end p 87
###begin p 88
(0.01 MB TXT)
###end p 88
###begin p 89
Click here for additional data file.
###end p 89
###begin p 90
We thank B. Vogelstein for providing HCT-116 p53 -/- cells. We are grateful to B. Chabot for critical reading of the manuscript and to L. Tora for anti-TAF antibodies.
###end p 90
###begin title 91
References
###end title 91
###begin article-title 92
The biochemistry of apoptosis.
###end article-title 92
###begin article-title 93
Apoptosis in the pathogenesis and treatment of disease.
###end article-title 93
###begin article-title 94
Inducible gene expression in apoptosis [In Process Citation].
###end article-title 94
###begin article-title 95
Transcriptional control of the core cell-death machinery.
###end article-title 95
###begin article-title 96
Regulation of apoptosis by alternative pre-mRNA splicing.
###end article-title 96
###begin article-title 97
p53 in health and disease.
###end article-title 97
###begin article-title 98
The ferredoxin reductase gene is regulated by the p53 family and sensitizes cells to oxidative stress-induced apoptosis.
###end article-title 98
###begin article-title 99
Ferredoxin reductase affects p53-dependent, 5-fluorouracil-induced apoptosis in colorectal cancer cells.
###end article-title 99
###begin article-title 100
PUMA induces the rapid apoptosis of colorectal cancer cells.
###end article-title 100
###begin article-title 101
Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis.
###end article-title 101
###begin article-title 102
###xml 66 71 <span type="species:ncbi:9606">human</span>
Tumor suppressor p53 is a direct transcriptional activator of the human bax gene.
###end article-title 102
###begin article-title 103
p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53.
###end article-title 103
###begin article-title 104
Regulation of gene expression by multiple forms of TFIID and other novel TAFII-containing complexes.
###end article-title 104
###begin article-title 105
TBP-associated factors (TAFIIs): multiple, selective transcriptional mediators in common complexes [In Process Citation].
###end article-title 105
###begin article-title 106
New problems in RNA polymerase II transcription initiation: matching the diversity of core promoters with a variety of promoter recognition factors.
###end article-title 106
###begin article-title 107
TAFs revisited: more data reveal new twists and confirm old ideas.
###end article-title 107
###begin article-title 108
The histone fold is a key structural motif of transcription factor TFIID.
###end article-title 108
###begin article-title 109
Structural similarity between TAFs and the heterotetrameric core of the histone octamer [see comments].
###end article-title 109
###begin article-title 110
###xml 37 42 <span type="species:ncbi:9606">human</span>
Crystal structure of a subcomplex of human transcription factor TFIID formed by TATA binding protein-associated factors hTAF4 (hTAF(II)135) and hTAF12 (hTAF(II)20).
###end article-title 110
###begin article-title 111
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human TAF(II)28 and TAF(II)18 interact through a histone fold encoded by atypical evolutionary conserved motifs also found in the SPT3 family.
###end article-title 111
###begin article-title 112
###xml 54 59 <span type="species:ncbi:4932">yeast</span>
Histone folds mediate selective heterodimerization of yeast TAF(II)25 with TFIID components yTAF(II)47 and yTAF(II)65 and with SAGA component ySPT7.
###end article-title 112
###begin article-title 113
###xml 21 26 <span type="species:ncbi:9606">human</span>
###xml 42 52 <span type="species:ncbi:7227">Drosophila</span>
###xml 104 109 <span type="species:ncbi:4932">yeast</span>
The TFIID components human TAF(II)140 and Drosophila BIP2 (TAF(II)155) are novel metazoan homologues of yeast TAF(II)47 containing a histone fold and a PHD finger.
###end article-title 113
###begin article-title 114
TAF4 nucleates a core subcomplex of TFIID and mediates activated transcription from a TATA-less promoter.
###end article-title 114
###begin article-title 115
Histone-like TAFs are essential for transcription in vivo.
###end article-title 115
###begin article-title 116
###xml 33 38 <span type="species:ncbi:4932">yeast</span>
Systematic analysis of essential yeast TAFs in genome-wide transcription and preinitiation complex assembly.
###end article-title 116
###begin article-title 117
###xml 78 102 <span type="species:ncbi:4932">Saccharomyces cerevisiae</span>
Identification and characterization of a TFIID-like multiprotein complex from Saccharomyces cerevisiae.
###end article-title 117
###begin article-title 118
###xml 4 15 <span type="species:ncbi:3702">Arabidopsis</span>
The Arabidopsis TFIID factor AtTAF6 controls pollen tube growth.
###end article-title 118
###begin article-title 119
###xml 63 73 <span type="species:ncbi:7227">Drosophila</span>
Developmental and transcriptional consequences of mutations in Drosophila TAF(II)60.
###end article-title 119
###begin article-title 120
###xml 48 57 <span type="species:ncbi:7955">zebrafish</span>
Identification of 315 genes essential for early zebrafish development.
###end article-title 120
###begin article-title 121
###xml 39 44 <span type="species:ncbi:9606">human</span>
Genomics and transcription analysis of human TFIID.
###end article-title 121
###begin article-title 122
###xml 26 36 <span type="species:ncbi:7227">Drosophila</span>
###xml 49 54 <span type="species:ncbi:9606">human</span>
Cloning and expression of Drosophila TAFII60 and human TAFII70 reveal conserved interactions with other subunits of TFIID.
###end article-title 122
###begin article-title 123
###xml 61 71 <span type="species:ncbi:7227">Drosophila</span>
###xml 75 81 <span type="species:ncbi:9606">humans</span>
###xml 114 124 <span type="species:ncbi:7227">Drosophila</span>
The downstream core promoter element, DPE, is conserved from Drosophila to humans and is recognized by TAFII60 of Drosophila.
###end article-title 123
###begin article-title 124
Core promoter binding by histone-like TAF complexes.
###end article-title 124
###begin article-title 125
p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60.
###end article-title 125
###begin article-title 126
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human TAFII31 protein is a transcriptional coactivator of the p53 protein.
###end article-title 126
###begin article-title 127
Functional interaction between p53, the TATA-binding protein (TBP), andTBP-associated factors in vivo.
###end article-title 127
###begin article-title 128
###xml 28 33 <span type="species:ncbi:10090">mouse</span>
A transactivation-deficient mouse model provides insights into Trp53 regulation and function.
###end article-title 128
###begin article-title 129
The p53QS transactivation-deficient mutant shows stress-specific apoptotic activity and induces embryonic lethality.
###end article-title 129
###begin article-title 130
Identification of hTAF(II)80 delta links apoptotic signaling pathways to transcription factor TFIID function.
###end article-title 130
###begin article-title 131
Modification of alternative splicing of Bcl-x pre-mRNA in prostate and breast cancer cells. analysis of apoptosis and cell death.
###end article-title 131
###begin article-title 132
Different TBP-associated factors are required for mediating the stimulation of transcription in vitro by the acidic transactivator GAL- VP16 and the two nonacidic activation functions of the estrogen receptor.
###end article-title 132
###begin article-title 133
Distinct domains of hTAFII100 are required for functional interaction with transcription factor TFIIF beta (RAP30) and incorporation into the TFIID complex.
###end article-title 133
###begin article-title 134
Normalization using weighted negative second order exponential error functions (NeONORM) provides robustness against asymmetries in comparative transcriptome profiles and avoids false calls.
###end article-title 134
###begin article-title 135
Avoiding inconsistencies over time and tracking difficulties in Applied Biosystems AB1700/Panther probe-to-gene annotations.
###end article-title 135
###begin article-title 136
TAFII70 isoform-specific growth suppression correlates with its ability to complex with the GADD45a protein.
###end article-title 136
###begin article-title 137
Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides [see comments].
###end article-title 137
###begin article-title 138
Cellular response to an antisense-mediated shift of Bcl-x pre-mRNA splicing and antineoplastic agents.
###end article-title 138
###begin article-title 139
Immunocytochemical detection and mapping of a cytokeratin 18 neo- epitope exposed during early apoptosis [In Process Citation].
###end article-title 139
###begin article-title 140
###xml 33 38 <span type="species:ncbi:9606">human</span>
Rearrangement of the p53 gene in human osteogenic sarcomas.
###end article-title 140
###begin article-title 141
###xml 80 85 <span type="species:ncbi:10090">mouse</span>
Endogenous HeLa p53 proteins are easily detected in HeLa cells transfected with mouse deletion mutant p53 gene.
###end article-title 141
###begin article-title 142
Requirement for p53 and p21 to sustain G2 arrest after DNA damage.
###end article-title 142
###begin article-title 143
High-sensitivity transcriptome data structure and implications for analysis and biologic interpretation.
###end article-title 143
###begin article-title 144
Large scale real-time PCR validation on gene expression measurements from two commercial long-oligonucleotide microarrays.
###end article-title 144
###begin article-title 145
###xml 10 15 <span type="species:ncbi:9606">human</span>
Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression.
###end article-title 145
###begin article-title 146
Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53.
###end article-title 146
###begin article-title 147
WAF1, a potential mediator of p53 tumor suppression.
###end article-title 147
###begin article-title 148
The multicoloured world of promoter recognition complexes.
###end article-title 148
###begin article-title 149
TAF7: a possible transcription initiation check-point regulator.
###end article-title 149
###begin article-title 150
Switching of the core transcription machinery during myogenesis.
###end article-title 150
###begin article-title 151
TAF4 inactivation in embryonic fibroblasts activates TGF beta signalling and autocrine growth.
###end article-title 151
###begin article-title 152
TAF9b (formerly TAF9L) is a bona fide TAF that has unique and overlapping roles with TAF9.
###end article-title 152
###begin article-title 153
###xml 52 62 <span type="species:ncbi:7227">Drosophila</span>
ATM and ATR pathways signal alternative splicing of Drosophila TAF1 pre-mRNA in response to DNA damage.
###end article-title 153
###begin article-title 154
DNA binding properties of TAF1 isoforms with two AT-hooks.
###end article-title 154
###begin article-title 155
###xml 0 11 <span type="species:ncbi:3702">Arabidopsis</span>
Arabidopsis enhanced ethylene response 4 encodes an EIN3-interacting TFIID transcription factor required for proper ethylene response, including ERF1 induction.
###end article-title 155
###begin article-title 156
Modeling the therapeutic efficacy of p53 restoration in tumors.
###end article-title 156
###begin article-title 157
Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy.
###end article-title 157
###begin p 158
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 158
###begin p 159
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: F.X.P. is recipient of a doctoral fellowship from the Nausicaa Combat Sa Leucemie association. A.B.'s group received funds from the European Hematology Association - Jose Carreras Foundation, and the French Ministry of Research through the "Complexite du Vivant - Action STICS-Sante" program. Work in B.B.'s laboratory was funded through a Discovery grant from Natural Sciences and Engineering Research Council of Canada. B.B. holds the Canada Research Chair in Genomic Regulation.
###end p 159

